CRISPR Therapeutics Reports Q1 Loss of $136 Million, Revenue Misses Estimates

CRISPR Therapeutics reported a wider-than-expected net loss of $136 million, or $1.58 per share, for the first quarter of 2025, missing analyst estimates and reflecting ongoing high investments in research and development. Quarterly revenue, primarily from grants, rose over 70% year-over-year to roughly $865,000 but still fell significantly short of expectations. Operating costs increased to $149.3 million, contributing to the company's continued financial challenges. Despite these results, CRISPR Therapeutics maintains a strong cash position of approximately $1.86 billion and continues to advance a promising pipeline, including its first approved gene-editing therapy, Casgevy, and new clinical milestones for programs like CTX310. Strategic partnerships, particularly with Vertex Pharmaceuticals, remain a key asset, supporting both development and commercialization efforts. However, the disappointing financial performance led to a notable decline in the company's stock price.